Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
REGENXBIO Inc. (RGNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights • Continued progress on ‘5x’25’ strategy to advance five AAV Therapeutics from REGENXBIO’s internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 • ABBV-RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie • Interim results from Phase II AAVIATE® and ALTITUDE® trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation • Additional interim efficacy data from the Phase II AAVIATE and ALTITUDE trials expected at upcoming medical conferences in second half 2023 and first half 2024 • Interim data f..."
06/05/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
02/28/2023 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights - Continued progress on ‘5x’25’ strategy to advance five AAV Therapeutics from REGENXBIO’s internal pipeline and licensed programs into pivotal-stage or commercial products by 2025 - RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie o Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials using subretinal delivery, expected to support BLA filing in 2024 o Recently announced interim data from the Phase II pharmacodynamic study supports use of NAVXpress™ platform process in future commercialization plans o Recently announced cohort expansions in AAVIATE® and ALTITUDE® suprachoroidal clinical tr..."
01/10/2023 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights"
06/07/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/25/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
03/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/01/2022 8-K Quarterly results
Docs: "REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights"
02/14/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE ™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery"
02/09/2022 8-K Quarterly results
11/15/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
11/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021"
11/09/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie"
11/02/2021 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights"
10/12/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE ™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting"
10/01/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO Presents Positive Initial Data from Phase II AAVIATE ® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54 th Annual Scientific Meeting"
09/13/2021 8-K Quarterly results
09/07/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
07/16/2021 8-K Other Events  Interactive Data
06/07/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
12/22/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"REGENXBIO Announces Agreement to Monetize Portion of Zolgensma ® Royalties for $200 Million - Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314 ROCKVILLE, Md., December 22, 2020 — REGENXBIO Inc. , a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it has entered into an agreement to sell a portion of the royalty rights due to REGENXBIO from Novartis Gene Therapies from the net sales of Zolgensma ® to entities managed by Healthcare Royalty Management, LLC for a gross purchase price of $200 million. This transaction provides immediate, non-dilutive capital to REGENXBIO f..."
11/04/2020 8-K Quarterly results
Docs: "REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights"
10/27/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG - Milestone payment based on achievement of $1.0 billion in cumulative net sales of Zolgensma ® - - Zolgensma is the first gene therapy based on REGENXBIO's NAV ® Technology Platform approved by the FDA and other regulatory authorities - ROCKVILLE, Md., October 27, 2020 — REGENXBIO Inc. , a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will receive a milestone payment of $80.0 million from Novartis AG based upon the achievement of $1.0 billion in cumulative net sales of Zolgensma. REGENXBIO expects to recognize this revenue in the third quarter of 2020. “Zolgensma is a transfo..."
08/06/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
06/01/2020 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy